Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia

NCT00821600 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.

NCT NCT00821600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00821600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2008
Completion date
June 30, 2009
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

psychotic disorders, schizophrenia